Literature DB >> 23523971

Standardization of terminology for episodes of hematopoietic stem cell patient transplant care.

C Fred LeMaistre1, Stephanie Farnia, Stephen Crawford, Joseph McGuirk, Richard T Maziarz, James Coates, Dennis Irwin, Patricia Martin, James L Gajewski.   

Abstract

The nomenclature describing hematopoietic stem cell transplantation has evolved, adding precision and definition in research and regulation. The lack of coordination and standardization in terminology has left some gaps in the definition of episodes of clinical care. These voids have caused particular problems in contracting for payment and billing for services rendered. The purpose of this report is to propose definitions for cell products, cell infusions, and transplantation episodes.
Copyright © 2013 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Year:  2013        PMID： 23523971     DOI： 10.1016/j.bbmt.2013.03.004

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN： 1083-8791            Impact factor:   5.742


  6 in total

1.  Costs of hematopoietic stem cell transplantation in a developing country.

Authors:  Monica M Rivera-Franco; Eucario Leon-Rodriguez; Haydee L Castro-Saldaña
Journal:  Int J Hematol       Date:  2017-06-14       Impact factor: 2.490

2.  Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation.

Authors:  Sergio A Giralt; Charles F LeMaistre; Navneet S Majhail; Stephanie H Farnia; Paul A Carpenter; Richard E Champlin; Stephen Crawford; David I Marks; James L Omel; Paul J Orchard; Jeanne Palmer; Wael Saber; Bipin N Savani; Paul A Veys; Christopher N Bredeson
Journal:  Biol Blood Marrow Transplant       Date:  2015-08-07       Impact factor: 5.742

3.  Reduced intensity conditioned allograft yields favorable survival for older adults with B-cell acute lymphoblastic leukemia.

Authors:  Veronika Bachanova; Wael Saber; Ashley Rosko; Hai-Lin Wang; Marcos de Lima; Brenda Sandmaier; H Jean Khoury; Andrew Artz; Johnathan Brammer; Christopher Bredeson; Sherif Farag; Mohamed Kharfan-Dabaja; Hillard M Lazarus; David I Marks; Rodrigo Martino Bufarull; Joseph McGuirk; Mohamed Mohty; Taiga Nishihori; Ian Nivison-Smith; Armin Rashidi; Olle Ringden; Matthew Seftel; Daniel Weisdorf
Journal:  Am J Hematol       Date:  2016-11-12       Impact factor: 10.047

Review 4.  Concise Review: The High Cost of High Tech Medicine: Planning Ahead for Market Access.

Authors:  Dawn Driscoll; Stephanie Farnia; Panos Kefalas; Richard T Maziarz
Journal:  Stem Cells Transl Med       Date:  2017-08       Impact factor: 6.940

5.  Longitudinal proteomics study of serum changes after allogeneic HSCT reveals potential markers of metabolic complications related to aGvHD.

Authors:  Sing Ying Wong; Seiko Kato; Frans Rodenburg; Arinobu Tojo; Nobuhiro Hayashi
Journal:  Sci Rep       Date:  2022-08-17       Impact factor: 4.996

6.  Five-year direct costs of acute lymphoblastic leukemia pediatric patients undergoing allogeneic stem cell transplant.

Authors:  Richard T Maziarz; Annie Guérin; Geneviève Gauthier; Julie Heroux; Maryia Zhdanava; Eric Q Wu; Simu K Thomas; Lei Chen
Journal:  Int J Hematol Oncol       Date:  2016-04-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.